A Phase 3 interventional study of Baricitinib and Placebo in COVID-19, sponsored by Eli Lilly and Company. Completed at 96 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing baricitinib in COVID-19 — 3 open to participants now, 4 under way, 3 of them phase 3. baricitinib · COVID-19.
Among the 20 studies testing baricitinib in COVID-19, this one is the 3rd largest by enrollment, is one of 13 that started in 2020, is one of 9 in phase 3, and was the 11th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →3 of the 20 studies testing baricitinib in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Wes Ely · Sites in United States
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2016; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,525 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 184 across the 20 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing baricitinib in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by polymerase chain reaction (PCR) test or other commercial or public health assay in any specimen, as documented by either of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 milligrams (mg) of baricitinib (given as two 2 mg tablets) administered orally every day (QD) with standard of care.
Drug: Baricitinib
Placebo (given as two placebo tablets) administered orally QD with standard of care.
Drug: Placebo
Given orally
Also known as: LY3009104
Given orally
Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])
Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO).
Time frame: Day 1 to Day 28
Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2
Percentage of participants who die or require non-invasive ventilation or invasive mechanical ventilation, including ECMO.
Time frame: Day 1 to Day 28
Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital
The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Participants with missing baseline ordinal scale values were excluded from analysis.
Time frame: Day 10
Number of Ventilator-Free Days
Number of days free of invasive mechanical ventilation.
Time frame: Day 1 to Day 28
Time to Recovery
Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day. NIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)
Time frame: Day 1 to Day 28
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
Time frame: Day 4
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
Time frame: Day 7
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
Time frame: Day 10
Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
Time frame: Day 14
Duration of Hospitalization
Duration of hospitalization.
Time frame: Days 1 to Day 28
Percentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline
Percentage of participants with a change in oxygen saturation from \< 94% to ≥ 94% from baseline based on National Early Warning Score (NEWS). Measure of the oxygen level of the blood is measure by pulse oximetry. The score is determined from six physiological parameters readily measured over time in hospitalized participants: Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness, as measured by Alert Voice Pain Unresponsive (AVPU). A score is assigned to each parameter, the magnitude of the score representing the extremity of variation from the norm. A weighting score is added for participants needing supplemental oxygen (oxygen delivery by mask or by cannula) The aggregate score is reflective of the participants status.
Time frame: Day 10
Overall Mortality
Number of deaths by Day 28.
Time frame: Day 1 to Day 28
Duration of Stay in the Intensive Care Unit (ICU) in Days
Duration of stay in the ICU in days.
Time frame: Day 1 to Day 28
Time to Clinical Deterioration (One-category Increase on the NIAID-OS)
The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. A higher score is representative of worse clinical outcome with a score of 8 being the highest and representing death.
Time frame: Day 1 to Day 28
Time to Resolution of Fever in Participants With Fever at Baseline
Time to resolution of fever in participants with fever at baseline was calculated using cox proportional hazard regression model adjusted for baseline disease severity (OS 4, OS 5, OS 6), age (\<65 years, \>=65 years), region (United States, Europe, rest of world), and systemic corticosteroids used at baseline for primary study condition (Yes/No).
Time frame: Day 1 to Day 28
Mean Change From Baseline on the National Early Warning Score (NEWS)
The NEWS score is used to detect and report changes in illness severity in participants with acute illness to identify participants at risk for poor outcomes. The score is based on six physiological parameters (Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness). A score is assigned to each parameter, and the sum of the score represents the participant's risk of poor outcomes with a minimum score of 0 representing the better outcome, a score of 7 or greater reflects high clinical risk for worsening and maximum score of 19 representing the worse outcome.
Time frame: Baseline, Day 4; Baseline, Day 7; Baseline, Day 10; Baseline, Day 14
Time to Definitive Extubation
Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.
Time frame: Day 1 to Day 28
Time to Independence From Non-Invasive Mechanical Ventilation
Time to independence from non-invasive mechanical ventilation was measured in days among participants who required non-invasive ventilation.
Time frame: Day 1 to Day 28
Time to Independence From Oxygen Therapy in Days
Time to independence from oxygen therapy in days.
Time frame: Day 1 to Day 28
Number of Days With Supplemental Oxygen Use
Number of days with supplemental oxygen use.
Time frame: Day 1 to Day 28
Number of Days of Resting Respiratory Rate <24 Breaths Per Minute
Number of days of resting respiratory rate \<24 breaths per minute.
Time frame: Day 1 to Day 28
| Milestone | Placebo + Standard of Care (SOC) | Baricitinib + SOC | Placebo + SOC Follow-Up | Baricitinib + SOC Follow-Up |
|---|---|---|---|---|
| Started | 761 | 764 | 0 | 0 |
| Received at least one dose of study drug | 752 | 750 | 0 | 0 |
| Completed | 604 | 644 | 0 | 0 |
| Not completed | 157 | 120 | 0 | 0 |
| Withdrew: Adverse event | 5 | 3 | 0 | 0 |
| Withdrew: Death | 98 | 61 | 0 | 0 |
| Withdrew: Lost to follow-up | 22 | 20 | 0 | 0 |
| Withdrew: Other-unknown | 15 | 9 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 12 | 0 | 0 |
| Withdrew: Randomized not dosed | 9 | 14 | 0 | 0 |
| Milestone | Placebo + Standard of Care (SOC) | Baricitinib + SOC | Placebo + SOC Follow-Up | Baricitinib + SOC Follow-Up |
|---|---|---|---|---|
| Started | 0 | 0 | 613 | 645 |
| Completed | 0 | 0 | 588 | 615 |
| Not completed | 0 | 0 | 25 | 30 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 |
| Withdrew: Death | 0 | 0 | 16 | 17 |
| Withdrew: Lost to follow-up | 0 | 0 | 7 | 7 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
| Withdrew: Still in hospital on ventilator at end of study | 0 | 0 | 1 | 0 |
| Withdrew: Left message, participant did not call back | 0 | 0 | 0 | 1 |
| Withdrew: Participant died | 0 | 0 | 0 | 1 |
| Withdrew: Participant was alive but did not respond to calls | 0 | 0 | 0 | 1 |
Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO).
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO]) | 30.5 (27.2 to 33.8) | 27.8 (24.6 to 31.0) |
Percentage of participants who die or require non-invasive ventilation or invasive mechanical ventilation, including ECMO.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2 | 27.1 (18.7 to 35.6) | 28.9 (19.6 to 38.2) |
The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Participants with missing baseline ordinal scale values were excluded from analysis.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital | 63.5 (60.1 to 67.0) | 65.0 (61.6 to 68.5) |
Number of days free of invasive mechanical ventilation.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Number of Ventilator-Free Days | 23.7 ± 0.39 | 24.5 ± 0.39 |
Recovery assessed by the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS). Time to reach NIAID-OS 1, 2, or 3 for the first time. The date reached is the first full day that OS 1, 2, or 3 is the participant's maximum OS for the day. NIAID-OS 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities and/or requiring home oxygen 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.)
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Time to Recovery | 11.0 (10.0 to 12.0) | 10.0 (9.0 to 11.0) |
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Day 4 NIAID-OS 1 | 4.6 (3.1 to 6.1) | 5.2 (3.6 to 6.8) |
| Day 4 NIAID-OS 2 | 1.5 (0.6 to 2.4) | 1.5 (0.6 to 2.4) |
| Day 4 NIAID-OS 3 | 0.8 (0.2 to 1.4) | 0.3 (0.0 to 0.7) |
| Day 4 NIAID-OS 4 | 19.4 (16.6 to 22.3) | 23.6 (20.6 to 26.7) |
| Day 4 NIAID-OS 5 | 41.0 (37.5 to 44.5) | 39.0 (35.5 to 42.5) |
| Day 4 NIAID-OS 6 | 22.4 (19.5 to 25.4) | 21.8 (18.9 to 24.8) |
| Day 4 NIAID-OS 7 | 8.9 (6.8 to 10.9) | 8.1 (6.2 to 10.1) |
| Day 4 NIAID-OS 8 | 1.4 (0.5 to 2.2) | 0.4 (0.0 to 0.9) |
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Day 7 NIAID-OS 1 | 20.2 (17.3 to 23.1) | 25.2 (22.1 to 28.4) |
| Day 7 NIAID-OS 2 | 6.6 (4.8 to 8.4) | 5.8 (4.1 to 7.5) |
| Day 7 NIAID-OS 3 | 0.5 (0.0 to 1.1) | 0.2 (0.0 to 0.5) |
| Day 7 NIAID-OS 4 | 21.2 (18.2 to 24.1) | 20.6 (17.6 to 23.5) |
| Day 7 NIAID-OS 5 | 22.5 (19.5 to 25.5) | 22.5 (19.4 to 25.5) |
| Day 7 NIAID-OS 6 | 14.5 (12.0 to 17.0) | 13.8 (11.3 to 16.2) |
| Day 7 NIAID-OS 7 | 11.2 (9.0 to 13.5) | 10.8 (8.6 to 13.0) |
| Day 7 NIAID-OS 8 | 3.3 (2.0 to 4.5) | 1.2 (0.4 to 2.0) |
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Day 10 NIAID-OS 1 | 37.7 (34.2 to 41.2) | 40.4 (36.9 to 44.0) |
| Day 10 NIAID-OS 2 | 9.4 (7.3 to 11.5) | 10.9 (8.7 to 13.2) |
| Day 10 NIAID-OS 3 | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.4) |
| Day 10 NIAID-OS 4 | 16.2 (13.6 to 18.9) | 14.1 (11.6 to 16.6) |
| Day 10 NIAID-OS 5 | 12.8 (10.3 to 15.2) | 12.4 (10.0 to 14.8) |
| Day 10 NIAID-OS 6 | 8.1 (6.1 to 10.0) | 8.9 (6.8 to 11.0) |
| Day 10 NIAID-OS 7 | 10.6 (8.4 to 12.9) | 10.4 (8.2 to 12.6) |
| Day 10 NIAID-OS 8 | 5.1 (3.5 to 6.7) | 2.6 (1.5 to 3.8) |
Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Day 14 NIAID-OS 1 | 51.6 (48.0 to 55.2) | 56.3 (52.7 to 59.9) |
| Day 14 NIAID-OS 2 | 11.2 (8.9 to 13.5) | 11.1 (8.8 to 13.4) |
| Day 14 NIAID-OS 3 | 0.3 (0.0 to 0.6) | 0.1 (0.0 to 0.4) |
| Day 14 NIAID-OS 4 | 8.0 (6.0 to 10.0) | 7.6 (5.7 to 9.6) |
| Day 14 NIAID-OS 5 | 8.4 (6.4 to 10.5) | 7.3 (5.4 to 9.2) |
| Day 14 NIAID-OS 6 | 3.6 (2.2 to 4.9) | 3.7 (2.3 to 5.1) |
| Day 14 NIAID-OS 7 | 9.4 (7.3 to 11.6) | 8.9 (6.9 to 11.0) |
| Day 14 NIAID-OS 8 | 7.5 (5.6 to 9.4) | 4.9 (3.4 to 6.5) |
Duration of hospitalization.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Duration of Hospitalization | 13.7 ± 0.40 | 12.9 ± 0.40 |
Percentage of participants with a change in oxygen saturation from \< 94% to ≥ 94% from baseline based on National Early Warning Score (NEWS). Measure of the oxygen level of the blood is measure by pulse oximetry. The score is determined from six physiological parameters readily measured over time in hospitalized participants: Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness, as measured by Alert Voice Pain Unresponsive (AVPU). A score is assigned to each parameter, the magnitude of the score representing the extremity of variation from the norm. A weighting score is added for participants needing supplemental oxygen (oxygen delivery by mask or by cannula) The aggregate score is reflective of the participants status.
| percentage of participants | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Percentage of Participants With a Change in Oxygen Saturation From < 94% to ≥ 94% From Baseline | 52.5 (46.7 to 58.2) | 56.7 (50.9 to 62.4) |
Number of deaths by Day 28.
| event of death | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Overall Mortality | 104 | 65 |
Duration of stay in the ICU in days.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Duration of Stay in the Intensive Care Unit (ICU) in Days | 3.17 ± 0.313 | 3.19 ± 0.315 |
The National Institute of Allergy and Infectious Diseases ordinal scale (NIAID-OS) is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. A higher score is representative of worse clinical outcome with a score of 8 being the highest and representing death.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Time to Clinical Deterioration (One-category Increase on the NIAID-OS) | NA (NA to NA) | NA (NA to NA) |
Time to resolution of fever in participants with fever at baseline was calculated using cox proportional hazard regression model adjusted for baseline disease severity (OS 4, OS 5, OS 6), age (\<65 years, \>=65 years), region (United States, Europe, rest of world), and systemic corticosteroids used at baseline for primary study condition (Yes/No).
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Time to Resolution of Fever in Participants With Fever at Baseline | 4.00 (3.00 to 4.00) | 3.00 (3.00 to 4.00) |
The NEWS score is used to detect and report changes in illness severity in participants with acute illness to identify participants at risk for poor outcomes. The score is based on six physiological parameters (Respiration rate; oxygen saturation; temperature; systolic blood pressure; heart (pulse) rate, and level of consciousness). A score is assigned to each parameter, and the sum of the score represents the participant's risk of poor outcomes with a minimum score of 0 representing the better outcome, a score of 7 or greater reflects high clinical risk for worsening and maximum score of 19 representing the worse outcome.
| score on a scale | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Day 4 | -0.59 ± 0.127 | -0.76 ± 0.125 |
| Day 7 | -0.86 ± 0.145 | -1.04 ± 0.143 |
| Day 10 | -1.33 ± 0.160 | -1.45 ± 0.158 |
| Day 14 | -1.41 ± 0.183 | -1.66 ± 0.182 |
Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Time to Definitive Extubation | NA (NA to NA) | NA (NA to NA) |
Time to independence from non-invasive mechanical ventilation was measured in days among participants who required non-invasive ventilation.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Time to Independence From Non-Invasive Mechanical Ventilation | 11.00 (9.00 to 13.00) | 12.00 (9.00 to 14.00) |
Time to independence from oxygen therapy in days.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Time to Independence From Oxygen Therapy in Days | 8.00 (8.00 to 9.00) | 8.00 (7.00 to 8.00) |
Number of days with supplemental oxygen use.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Number of Days With Supplemental Oxygen Use | 4.60 ± 0.221 | 4.37 ± 0.222 |
Number of days of resting respiratory rate \<24 breaths per minute.
| days | Placebo + SOC | Baricitinib + SOC |
|---|---|---|
| Number of Days of Resting Respiratory Rate <24 Breaths Per Minute | 9.62 ± 0.300 | 9.73 ± 0.304 |
Collected over Baseline up to 119 days Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 104/752 (13.8%) | 135/752 (18%) | 0/752 (0%) |
| 4 Milligrams (mg) Baricitinib | 65/750 (8.7%) | 110/750 (14.7%) | 0/750 (0%) |
| Placebo Follow-up | 16/613 (2.6%) | 12/613 (2%) | 0/613 (0%) |
| 4mg Baricitinib Follow-up | 18/645 (2.8%) | 18/645 (2.8%) | 0/645 (0%) |
| Event | Placebo | 4 Milligrams (mg) Baricitinib | Placebo Follow-up | 4mg Baricitinib Follow-up |
|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 29/752 | 17/750 | 1/613 | 2/645 |
| Septic shockInfections and infestations | 24/752 | 13/750 | 4/613 | 5/645 |
| Covid-19 pneumoniaInfections and infestations | 21/752 | 21/750 | 0/613 | 0/645 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 17/752 | 10/750 | 0/613 | 1/645 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/752 | 12/750 | 0/613 | 0/645 |
| Covid-19Infections and infestations | 10/752 | 8/750 | 1/613 | 1/645 |
| PneumoniaInfections and infestations | 10/752 | 8/750 | 0/613 | 1/645 |
| Acute kidney injuryRenal and urinary disorders | 10/752 | 7/750 | 1/613 | 0/645 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/752 | 6/750 | 0/613 | 0/645 |
| Cardio-respiratory arrestCardiac disorders | 6/752 | 3/750 | 1/613 | 1/645 |
All participants randomly assigned to study intervention. Participants were analyzed according to the intervention to which they were assigned.
| Age, Continuous(years) | Placebo +SOC | Baricitinib + SOC | Total |
|---|---|---|---|
| Mean | 57.5 ± 13.8 | 57.8 ± 14.3 | 57.6 ± 14.1 |
| Sex: Female, Male(Participants) | Placebo +SOC | Baricitinib + SOC | Total |
|---|---|---|---|
| Female | 288 | 274 | 562 |
| Male | 473 | 490 | 963 |
| Race (NIH/OMB)(Participants) | Placebo +SOC | Baricitinib + SOC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 168 | 148 | 316 |
| Asian | 94 | 80 | 174 |
| Native Hawaiian or Other Pacific Islander | 2 | 3 | 5 |
| Black or African American | 36 | 39 | 75 |
| White | 440 | 480 | 920 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 20 | 12 | 32 |
| Region of Enrollment(Participants) | Placebo +SOC | Baricitinib + SOC | Total |
|---|---|---|---|
| Puerto Rico | 3 | 8 | 11 |
| Argentina | 101 | 107 | 208 |
| United States | 155 | 154 | 309 |
| Japan | 19 | 19 | 38 |
| United Kingdom | 7 | 4 | 11 |
| India | 31 | 19 | 50 |
| Russia | 54 | 58 | 112 |
| Spain | 42 | 45 | 87 |
| South Korea | 20 | 16 | 36 |
| Brazil | 165 | 172 | 337 |
| Mexico | 143 | 138 | 281 |
| Italy | 10 | 15 | 25 |
| Germany | 11 | 9 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting
Access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting
Data sharing details ↗ · vivli.org
Ran from Jun 2020 to primary completion in Feb 2021, 8 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib